Parvovirus need not be a death sentence
Virbagen® Omega contains recombinant interferon omega of feline origin. Type I interferons are cytokines that act as protein messengers which induce multiple immune pathways in the cell. These include the increased production of potent anti-viral proteins and enzymes. Licensed to treat Canine Parvovirus, Virbagen® Omega is administered intravenously and is proven to decrease mortality rate when used in conjunction with supportive therapies.
Product Features & Benefits:
Licensed for the treatment of parvovirus in dogs
Mortality in dogs is reduced by 4.4x when using Virbagen® Omega in combination with supportive therapy rather than supportive therapy alone.1
When looking specifically at an unvaccinated population, the use of Virbagen® Omega decreases mortality by 6.4 times
Reduces clinical signs of parvovirus to facilitate a quicker recovery1
The canine dose 2.5 MU/Kg IV once daily for 3 days.Use in a 10kg dog would require 25MU per day and therefore 75MU for the course. One vial of reconstituted Virbagen® Omega contains 10MU of interferon,which would result in 2.5 vials per day for this example
Licensed, also, to treat FeLV and FIV/FeLV co-infected cats where it is proven to:
Significantly reduce the clinical signs
Decrease overall mortality rate
Improve overall quality of life
Available in 2 and 5 vial packs.
Use medicines responsibly. www.noah.co.uk/responsible.
Further information is available on the SPC or on request from Virbac Ltd.
1. K. De Mari et al. Treatment of canine parvovirus enteritis with interferon-omega in a placebo-controlled field trial, Veterinary Record (2003) 152, 105-108.